{"version":"1.0","provider_name":"Allphase Pharma Consulting, LLC","provider_url":"https:\/\/allphasepharma.com\/dir","author_name":"Harald","author_url":"https:\/\/allphasepharma.com\/dir\/author\/haraldeva\/","title":"Nominating Thiamphenicol for IDSA\u2019s 10 x \u201920 Campaign - Allphase Pharma Consulting, LLC","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"RTaHirutGs\"><a href=\"https:\/\/allphasepharma.com\/dir\/2014\/12\/19\/1178\/nominating-thiamphenicol-for-idsas-10-x-20-campaign\/\">Nominating Thiamphenicol for IDSA\u2019s 10 x \u201920 Campaign<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/allphasepharma.com\/dir\/2014\/12\/19\/1178\/nominating-thiamphenicol-for-idsas-10-x-20-campaign\/embed\/#?secret=RTaHirutGs\" width=\"600\" height=\"338\" title=\"&#8220;Nominating Thiamphenicol for IDSA\u2019s 10 x \u201920 Campaign&#8221; &#8212; Allphase Pharma Consulting, LLC\" data-secret=\"RTaHirutGs\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/allphasepharma.com\/dir\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/12\/Thiamphenicol-slider-copy.jpg?fit=640%2C180&ssl=1","thumbnail_width":640,"thumbnail_height":180,"description":"If you were developing a new antibiotic with a novel MoA, one that covers most GPC, most GNR, most anaerobes and atypicals, including many MDR pathogens like MRSA, enterococci (both E. faecalis and E. faecium), and one that has also activity against\u00a0rickettsiae and bioterrorism agents, you would consider it a Continue reading  &rarr;"}